ArticleDrug and alcohol dependence2017
Maternal buprenorphine treatment and infant outcome.
Article in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Effects of prenatal opioid exposure on infant sympathetic and parasympathetic nervous system activity.Psychophysiology · 2024Article
- Sex differences in neonatal outcomes following prenatal opioid exposure.Frontiers in pediatrics · 2024Review
- Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.Neurotoxicology · 2023Article
- Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.Acta obstetricia et gynecologica Scandinavica · 2023Article
- A review of the genomics of neonatal abstinence syndrome.Frontiers in genetics · 2023Review
- Rates of substance and polysubstance use through universal maternal testing at the time of delivery.Journal of perinatology : official journal of the California Perinatal Association · 2022Article
- Prevalence of marijuana use in pregnant women with concurrent opioid use disorder or alcohol use in pregnancy.Addiction science & clinical practice · 2022Article
- Improving translational relevance: The need for combined exposure models for studying prenatal adversity.Brain, behavior, & immunity - health · 2021Article
- Neonatal Outcomes after Combined Opioid and Nicotine Exposure in Utero: A Scoping Review.International journal of environmental research and public health · 2021Article
- Polysubstance Use Among Pregnant Women With Opioid Use Disorder in the United States, 2007-2016.Obstetrics and gynecology · 2020Article
- Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization.The Journal of pediatrics · 2020Article
- Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings.Journal of substance abuse treatment · 2020Article
- Inclusion of Positive Self-reporting by Mothers of Substance Exposed Neonates Increases the Predictability of NAS Severity Over Toxicology Alone.Maternal and child health journal · 2020Article
- Prenatal opioid exposure: The next neonatal neuroinflammatory disease.Brain, behavior, and immunity · 2020Article
- Opioid Use in Pregnancy.Current psychiatry reports · 2019Review
- Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.CNS drugs · 2019Review
- Optimal Care for NAS: Are We Moving in the Wrong Direction?Hospital pediatrics · 2019Review
- Effects of opioids on the parental brain in health and disease.Frontiers in neuroendocrinology · 2019Review
- A 12-month follow-up of infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use.Neurotoxicology and teratologyArticle
- Gestational buprenorphine-naloxone exposure and fetal neurobehavior.Neurotoxicology and teratologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesMaternal buprenorphine maintenance predisposes the infant to exhibit neonatal abstinence syndrome (NAS), but there is insufficient published information regarding the nature of NAS and factors that contribute to its severity in buprenorphine-exposed infants.
methodsThe present study evaluated forty-one infants of buprenorphine-maintained women in comprehensive substance use disorder treatment who participated in an open-label study examining the effects of maternal buprenorphine maintenance on infant outcomes. Modifiers of the infant outcomes, including maternal treatment and substance use disorder parameters, were also evaluated.
resultsFifty-nine percent of offspring exhibited NAS that required pharmacologic management. Both maternal buprenorphine dose as well as prenatal polysubstance exposure to illicit substance use/licit substance misuse were independently associated with NAS expression. Polysubstance exposure was associated with more severe NAS expression after controlling for the effects of buprenorphine dose. Other exposures, including cigarette smoking and SRI use, were not related to outcomes. Maternal buprenorphine dose was positively associated with lower birth weight and length.
conclusionsPolysubstance exposure was the most potent predictor of NAS severity in this sample of buprenorphine-exposed neonates. This finding suggests the need for interventions that reduce maternal polysubstance use during medication assisted treatment for opioid use disorder, and highlights the necessity of a comprehensive approach, beyond buprenorphine treatment alone, for the optimal care for pregnant women with opioid use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.